New Xenotransplantation Guidelines Adopted In UK

3 February 1997

The UK has put in place an effective ban on the conduct of humanclinical trials of xenotransplantation, pending the appointment of a regulatory authority to oversee the developments in the field until there is an opportunity to put primary legislation in place (Marketletter January 20).

Stephen Dorrell, the UK Secretary of State for Health, said on January 16 that the government was accepting the recommendations put forward by the Advisory Group on the Ethics of Xenotransplantation in its report on the issue.

The report's main conclusion is that it is not currently acceptable to move to trials involving humans, "due to the lack of knowledge at the present time concerning aspects of physiology, immunology and risk of infection."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight